Multifocal motor neuropathy

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

Retrieved on: 
Thursday, May 9, 2024
Janus, American Academy, Magic, Myasthenia gravis, Investment, Acetylcholine, Research, PIPE, Dianthus, Form, YTE, Therapy, Patient, Chemistry, CMC, AAN, Information, Multifocal motor neuropathy, Expense, G&A, CIDP, Clinical trial, Annual general meeting, GMG, Complement component 1s, MMN, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the first quarter ending March 31, 2024, and provided an update on recent business achievements.

Key Points: 
  • “The first quarter of 2024 was highlighted by the initiation of our Phase 2 MaGic trial of DNTH103 for patients with gMG.
  • Initial top-line results from this trial are anticipated to be available in the second half of 2025.
  • Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
  • Additional Information - For additional information on the Company’s financial results for the quarter ended March 31, 2024, please refer to the Form 10-Q filed with the SEC.

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Thursday, May 9, 2024
MuSK protein, FDA, ARDA, IND, PDUFA, Medicine, Autoimmunity, Efgartigimod alfa, Glomerulonephritis, CMS, Inflammation, ITP, IIP, ALS, Alfa Romeo, C2, Therapy, Systemic scleroderma, Safety, Euronext, Nektar, DGF, Sjögren syndrome, CIDP, Biology, IL-6, Nektar Therapeutics, GMG, TED, File, MMN, Lupus nephritis, Kidney, AMR, Multifocal motor neuropathy, Patient, Congenital myasthenic syndrome, Immune system, Dermatomyositis, Growth, Amgen, Pharmaceutical industry

“The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “The team at argenx has made significant progress executing across the ambitious plan we set out at the beginning of the year,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • “We are driven by our commitment to provide patients with the broadest gMG product offering that consistently delivers on safety and efficacy.
  • VYVGART SC played a key role in our growth over the quarter, expanding the breadth of our prescriber base and reaching new patients.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

Retrieved on: 
Thursday, April 11, 2024
American Academy, Myasthenia gravis, Risk, Safety, Infection, Dianthus, Neonatal Fc receptor, Therapy, Patient, AAN, Multifocal motor neuropathy, Caregiver, Complement component 1s, GMG, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually.

Key Points: 
  • NEW YORK and WALTHAM, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced an oral presentation for DNTH103 at the American Academy of Neurology (AAN) Annual Meeting, taking place April 13-18, 2024 in Denver, Colorado and virtually.
  • DNTH103 is an investigational classical pathway inhibitor that is uniquely specific to the active form of C1s, and is being evaluated for its potential as an effective, low-volume, convenient and safe treatment option for patients with generalized Myasthenia Gravis, Multifocal Motor Neuropathy, and Chronic Inflammatory Demyelinating Polyneuropathy.
  • The oral presentation at AAN will highlight preclinical and in vitro data describing the differentiated safety profile and neurotransmission activity of DNTH103 and a review of previously released Phase 1 healthy volunteer data.
  • “We aim to demonstrate that DNTH103 may be a best-in-class treatment option with improved safety and infrequent self-administration that provides effective and consistent control of symptoms for people living with neuromuscular conditions.”
    Detailed presentation listings for the 2024 AAN Annual Meeting can be found on the meeting website: https://www.aan.com/events/annual-meeting .

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Janus, Research, MMN, Myasthenia gravis, Dianthus, GMG, CIDP, Half-life, Form, Patient, Complement component 1s, Magenta, Acetylcholine, American Academy, CMC, G&A, YTE, Drug, AAN, Investment, Therapy, PIPE, Magic, Multifocal motor neuropathy, Annual general meeting, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023, and provided an update on recent business achievements.

Key Points: 
  • DNTH103 has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
  • Initial top-line results from this trial are anticipated to be available in the second half of 2025.
  • Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
  • Additional Information – For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the SEC.

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Retrieved on: 
Thursday, February 29, 2024
DGF, Neonatal Fc receptor, ALS, Congenital myasthenic syndrome, CMS, CIDP, MMN, Alfa Romeo, IIP, IL-6, FDA, Inflammation, MHLW, PDUFA, Euronext, Neurology, MuSK protein, Kidney, ARDA, Health care, C2, GMG, Ministry of Health, Dermatomyositis, Patient, Efgartigimod alfa, MHRA, Medicine, Multifocal motor neuropathy, Immune system, Pharmaceutical industry

“argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.

Key Points: 
  • “argenx reached thousands of new patients and their families in 2023 by delivering on our commitment to make VYVGART available to the global MG community,” said Tim Van Hauwermeiren, Chief Executive Officer of argenx.
  • Clinically, we generated significant data through multiple study readouts, achieving key milestones for both the CIDP and MMN patient communities and importantly advancing our second molecule, empasiprubart.
  • Looking forward to 2024, we will act with a continued sense of purpose to expand our patient reach.
  • In addition, argenx is evaluating ARGX-119, a muscle-specific kinase (MuSK) agonist in both congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS).

argenx Highlights 2024 Strategic Priorities

Retrieved on: 
Monday, January 8, 2024
Immunoglobulin therapy, GMG, FDA, PRV, Congenital myasthenic syndrome, ARDA, Research Councils UK, Euronext, Inflammation, Cohort, PGIC, NRDL, Autoimmunity, Efgartigimod alfa, Dermatomyositis, Conference, MuSK protein, IND, CIDP, Pharmacokinetics, MMN, Safety, Therapy, Patient, ALS, Immune system, IL-6, Medicine, International Myeloma Foundation, IIP, FSS, Neonatal Fc receptor, Multifocal motor neuropathy, Growth, Pharmaceutical industry

argenx is planning to reach more patients commercially in 2024 through its multi-dimensional expansion efforts.

Key Points: 
  • argenx is planning to reach more patients commercially in 2024 through its multi-dimensional expansion efforts.
  • In addition, ARGX-119, a muscle-specific kinase (MuSK) agonist, will initiate Phase 1b/2a studies in congenital myasthenic syndrome and amyotrophic lateral sclerosis in 2024.
  • As of December 31, 2023, argenx had approximately $3.2 billion in cash, cash equivalents and current financial assets*.
  • Based on its current operating plans, argenx expects its combined R&D and SG&A expenses in 2024 to be less than $2 billion.

Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer

Retrieved on: 
Wednesday, November 29, 2023
Ruff, Biology, University, Pfizer, Corporate Affairs, Biotechnology, Corporate communication, Fred Hutchinson, Drug development, CMC, FC, Molecular biology, Complement component 1s, MGI, Neuro, Therapy, Columbia University, Doctor of Philosophy, Multifocal motor neuropathy, Publication, Patient, Dianthus, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer. In this role, Dr. Stavenhagen will lead the Company’s discovery and preclinical research and translational science initiatives.

Key Points: 
  • In this role, Dr. Stavenhagen will lead the Company’s discovery and preclinical research and translational science initiatives.
  • “I’m thrilled to welcome Jeff to the Dianthus team as we advance next-generation antibody therapeutics for patients living with severe autoimmune diseases.
  • He was most recently Chief Scientific Officer at Therini Bio, where he directed R&D initiatives leading to the development of a first-in-class monoclonal antibody for the treatment of neurodegenerative diseases.
  • She earned a master’s degree in biotechnology from Northwestern University and a bachelor’s degree in biology from the University of Iowa.

Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
MMN, Muscle contraction, Therapy, Multifocal motor neuropathy, Investment, Disease, Risk, Form, Magenta, GMG, Patient, Complement component 1s, Research, CIDP, Bacteria, Half-life, Infection, Dianthus, YTE, Vaccine, Pharmaceutical industry, Airline, Cryptocurrency

Top-line Phase 1 data across seven single and multiple ascending dose cohorts with 52 healthy volunteers establish DNTH103’s best-in-class potential.

Key Points: 
  • Top-line Phase 1 data across seven single and multiple ascending dose cohorts with 52 healthy volunteers establish DNTH103’s best-in-class potential.
  • Research and development expenses for the quarter ended September 30, 2023 were $8.0 million, inclusive of $0.4 million of stock-based compensation.
  • Net loss for the quarter ended September 30, 2023 was $14.8 million or $3.78 net loss per share (basic and diluted).
  • For additional information on the Company’s financial results for the quarter ended September 30, 2023, please refer to the Form 10-Q filed with the SEC.

NEUROPATHY ACTION FOUNDATION (NAF) TO HOST FREE VIRTUAL PATIENT EDUCATION EVENT ON MULTIFOCAL MOTOR NEUROPATHY (MMN)

Retrieved on: 
Thursday, October 12, 2023
Diagnosis, Disease, Immune system, MMN, Disability, Weakness, Sensation, NAF, Diabetic neuropathy, Patient, Quality of life, Multifocal motor neuropathy, Nursing

SANTA ANA, Calif. , Oct. 12, 2023 /PRNewswire/ -- The Neuropathy Action Foundation (NAF), a 501(c)(3) non-profit dedicated to providing neuropathy patients with the resources necessary to improve their quality of life, today announced that it will host a free one-hour virtual webinar to educate participants about Multifocal Motor Neuropathy (MMN), including signs and symptoms, incidences and causes, and the importance of accurate and early diagnosis. Details for the event include:

Key Points: 
  • Details for the event include:
    "The process to detect and treat Multifocal Motor Neuropathy can be lengthy and difficult, and MMN patients are often misdiagnosed, which presents additional challenges for patients experiencing symptoms," said NAF President Dominick Spatafora.
  • "The mission of the Neuropathy Action Foundation is to equip neuropathy patients and their families with the resources necessary to improve their quality of life, and this free educational event is a continuation of our decades-long commitment to empowering people living with MMN."
  • Multifocal Motor Neuropathy (MMN) is a rare condition in which multiple motor nerves are attacked by one's immune system.
  • Most patients are in their 40s to 60s, although MMN has been described between the ages of 20 and 80.

Dianthus Therapeutics Announces Positive Top-line Phase 1 Data and Debuts Trading on Nasdaq as DNTH

Retrieved on: 
Tuesday, September 12, 2023
Complement component 1s, Multifocal motor neuropathy, CIDP, Therapy, Half-life, GMG, Pathology, Myasthenia gravis, MMN, Patient, Dianthus, Vaccine, Pharmaceutical industry

NEW YORK and WALTHAM, Mass., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced positive top-line Phase 1 data for DNTH103 validating its best-in-class potential as a selective classical pathway inhibitor targeting only the active form of the C1s protein. Additionally, Dianthus will begin trading on the Nasdaq Capital Market today as DNTH, following the successful completion on September 11, 2023 of the previously announced merger with Magenta Therapeutics (“Magenta”).

Key Points: 
  • Additionally, Dianthus will begin trading on the Nasdaq Capital Market today as DNTH, following the successful completion on September 11, 2023 of the previously announced merger with Magenta Therapeutics (“Magenta”).
  • The Phase 1 healthy volunteer study was designed to validate the extended half-life, potent classical pathway inhibition, and potentially differentiated safety profile of DNTH103.
  • Additional information about our Phase 1 data and DNTH103 can be found in our corporate presentation at investor.dianthustx.com .
  • “These results, combined with our transition to the public markets, represent a major milestone in our growth trajectory.